Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284);International uniform response criteria for multiple myeloma

Leukemia

Volumn 20, Issue 9, 2006, Pages 1467-1473

  Durie, B G M ^a   Harousseau, J L ^b   Miguel, J S ^c   Blade J ^d   Barlogie, B ^e   Anderson, K ^f   Gertz, M ^g   Dimopoulos, M ^h   Westin, J ⁱ   Sonneveld, P ^j   Ludwig, H ^k   Gahrton, G ^l   Beksac, M ^m   Crowley, J ⁿ   Belch, A ^o   Boccadaro, M ^p   Cavo, M ^z   Turesson, I ^q   Joshua, D ^r   Vesole, D ^s   Kyle, R ^g   Tricot, G ^e   Alexanian, R ^t   Attal, M ^u   Merlini, G ^v   Powles, R ^w   Richardson, P ^x   Shimizu, K ^y   Tosi, P ^z   Rajkumar, S V ^g   Morgan, G ^aa   more..

^a Aptium Oncology Inc   (United States)

^b INSTITUT DE BIOLOGIE   (France)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f DFCI   (United States)

^g MAYO CLINIC   (United States)

^h ALEXANDRA HOSPITAL   (Greece)

ⁱ LUND UNIVERSITY   (Sweden)

^j Wilhelminenspital Der Stat Wien ^*

^k WILHELMINEN HOSPITAL   (Austria)

^l KAROLINSKA INSTITUTE   (Sweden)

^m ANKARA UNIVERSITY   (Turkey)

ⁿ Fred Hutchinson Cancer Research Center   (United States)

^o CROSS CANCER INSTITUTE   (Canada)

^p UNIVERSITY OF TURIN   (Italy)

^q MALMÖ UNIVERSITY   (Sweden)

^r ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^s ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^t UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^u CHU PURPAN   (France)

^v UNIVERSITY OF PAVIA   (Italy)

^w The Leukemia and Myeloma Program   (United Kingdom)

^x DANA FARBER CANCER INSTITUTE   (United States)

^y Nagoya City Midori General Hospital   (Japan)

^z UNIVERSITY OF BOLOGNA   (Italy)

^aa ROYAL MARSDEN HOSPITAL   (United Kingdom)

more..

Author keywords

Clinical outcomes; Myeloma; Response criteria; Staging; Survival duration; Uniform criteria

Indexed keywords

M PROTEIN; MELPHALAN; PREDNISONE; THALIDOMIDE;

ACCURACY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER REGISTRY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG RESPONSE; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RELIABILITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84988241358     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404582     Document Type: Erratum

References (29)

1. Durie BGM. New approaches to treatment for multiple myeloma: Durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 2005; 6: 181-190.
2. Rajkumar SV, Dispenzieri A. Evaluation and monitoring of response to therapy in multiple myeloma. Haematologica 2005; 90: 1305-1308.
3. Child JA, Morgan G, Davies F, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
4. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 26: 2495-2502.
5. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
6. Durie BGM, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: Importance of time to progression in Southwest Oncology Group chemotherapy trials. J Clin Oncol 2004; 22: 1857-1863.
7. Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR et al. POEMS syndrome: Definitions and long-term outcome. Blood 2003; 101: 2496-2506.
8. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
9. Greipp PR, San Miguel J, Durie BGM, Crowley J, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
10. Durie BGM. Staging and kinetics in multiple myeloma. In: Salmon SE (ed). Clinics in Haematology: Myeloma and Related Disorders, Vol. 2, Number 1, WB Saunders Company, Ltd: Alden Press, Ocford, 1982, pp 3-18.
11. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
12. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755-762.
13. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902.
14. Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum testing for assessment of patients with Bence-Jones myeloma. Lancet 2003; 361: 489-491.
15. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child A, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004; 126: 348-354.
16. Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T et al. Doxorubicin and dexmaethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Hematol 2006; 132: 155.
17. Rajkumar SV, Kyle RA, Therneau TM, Melton III LJ, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-817.
18. Kyle RA, Schreiman JS, McLeod RA, Beabout JW. Computed tomography in diagnosis and management of multiple myeloma and its variants. Arch Int Med 1985; 145: 1451-1452.
19. 18PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457-1463.
20. Durie BGM. Is magnitude of initial response predictive for survival in multiple myeloma? Ann Oncol 1999; 2: 166-169.
21. Lahuerta JJ, Martinez-Lopez J, de la Serna J, Blade J, Grande C, Alegra A et al. Remission status defined by immunofixation versus electrophoresis following autologus transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000; 109: 438-446.
22. Riccardi A, Mora O, Tinelli C, Porta C, Danova M, Brugnatelli S et al. Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: Results of the MM87 prospective randomized protocol. Eur J Cancer 2003; 39: 31-37.
23. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexmaethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 359.
24. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
25. Rajkumar SV, Dispenzieri A. Evaluation and monitoring of response to therapy in multiple myeloma. Haematologica 2005; 90: 1305-1308.
26. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup trial S9321. J Clin Oncol 2006; 24: 929-936.
27. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
28. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone therapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: A randomized controlled trial. Lancet 2006; 367: 825-831.
29. Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037-1043.